Filing summary
Entity mismatch: The request identifies Axe Compute Inc., but the supplied Form 10-K is for BioDrain Medical, Inc. The summary below reflects the filing text, not Axe Compute. This is an annual report for the fiscal year ended December 31, 2011, filed April 16, 2012; it is not a standalone fourth-quarter report.
Business context
BioDrain describes itself as an early-stage medical-device company developing and selling the Streamway Fluid Management System (FMS), a wall-mounted device intended to collect, measure, and dispose of surgical fluids directly into a hospital sewer. Its business model also depends on sales of proprietary disposable cleaning kits. The company reported limited commercial activity: five Streamway systems sold in 2011. The FMS had FDA 510(k) clearance and had been used in more than 700 live surgeries, according to the filing.
Financial performance and liquidity
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $96,637 | $288 |
| Cost of goods sold | $56,080 | $140 |
| Gross profit | $40,557 | $148 |
| Gross margin | 42% | Not stated |
| General and administrative expense | $3,561,566 | $1,874,465 |
| Operations expense | $351,662 | $276,998 |
| Sales and marketing expense | $232,716 | $199,593 |
| Interest expense | $230,374 | $147,093 |
| Net loss | $4,486,879 | $1,352,709 |
| Net loss per share, basic and diluted | $0.18 | $0.11 |
| Net cash used in operating activities | $1,781,631 | $820,681 |
At December 31, 2011, cash was $122,985, total current assets were $301,032, and total assets were $446,220. Current liabilities were $2,353,268; long-term debt and convertible debt, net of discounts, were $630,153. Stockholders’ deficit was $2,703,264 and accumulated deficit was $11,868,956. The balance sheet indicates very limited liquidity relative to current obligations. The filing gives no clear consolidated debt total including all instruments and accrued obligations.
Cash increased from $9,383 at year-end 2010 to $122,985 at year-end 2011, primarily as financing provided $1,895,233, including $1,386,000 from stock issuance and $525,500 from debt. Investing cash flow was zero. Management reported operating expenses of about $100,000 per month and estimated at least $2 million of additional financing would be needed to fund the next 12 months.
Changes versus the prior year
- Revenue rose from $288 to $96,637, reflecting five system sales and disposable supplies; commercial scale remained very small.
- Net loss increased by about $3.13 million, while operating cash use increased by about $961,000.
- G&A rose by about $1.69 million, primarily from higher consulting and investor-relations expenses; operations and sales and marketing expenses also increased.
- Interest expense rose as debt and related debt-discount amortization increased. The valuation of equity-linked instruments shifted from a $1.145 million gain in 2010 to a $151,118 loss in 2011, contributing to the year-over-year deterioration in reported results.
- Cash and inventory increased, but so did current convertible debt and the overall stockholders’ deficit. Common shares outstanding increased from 14.0 million to 32.1 million during 2011.
Outlook, risks, contingencies, and unusual items
- Going concern and funding: The auditor’s report states that recurring losses, accumulated deficit, and lack of significant product revenue raise substantial doubt about the company’s ability to continue as a going concern. The company said it expected cash to last approximately through June 30, 2012 and sought at least $2 million in financing; availability and terms were uncertain and could be highly dilutive.
- Debt pressure: Management disclosed approximately $2.382 million of debts, liabilities, and cash obligations coming due in the second and third quarters of 2012. As of April 10, 2012, $682,000 of principal and accrued interest was past due and in default; holders of $382,000 had threatened legal action. The filing’s debt schedule separately lists $1.084 million of principal payments due in 2012.
- Subsequent financing and related-party terms: In March 2012, SOK Partners, affiliated with company insiders, agreed to provide a secured convertible note of up to $600,000 at 20%, due August 2012, with conversion and equity-bonus provisions. The company also documented a $240,000 secured 20% convertible note due June 2012 for prior advances to Dr. Herschkowitz. Default provisions, additional equity transfers, and restrictions on other financing may affect dilution, control, and asset claims.
- Commercial execution: Management expected system revenue to increase if hospital evaluations led to orders, but gave no quantified sales forecast. Risks include slow adoption, installation and plumbing costs, competition from larger companies, production capacity, and the need for additional financing to scale manufacturing and distribution.
- Legal and intellectual property: A former sales executive sued in January 2012 alleging breach of contract and defamation; the company intends to defend the action. The company also disclosed potential patent ownership or contract claims by former collaborators, which it disputes, and a 4% royalty on FMS sales payable to the patent inventor for the patent term.
- Controls and accounting: Management concluded disclosure controls were ineffective at year-end and reported a material weakness involving stock-option and warrant records and a large adjustment between equity value and compensation expense. The filing says these audit adjustments materially affected 2011 financial position and results; remediation was planned.
- Other risks: The company had only three full-time employees, limited public-market liquidity, and no history of profitability. Its common stock was thinly traded, and the filing warned of dilution, penny-stock trading constraints, and possible loss of the investment.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is BioDrain Medical, Inc., not Axe Compute Inc.
- Review the audited financial statements and notes for debt maturities, defaults, security interests, convertible terms, and subsequent-event accounting.
- Confirm the status and actual funding received under the 2012 SOK Partners and Herschkowitz arrangements, including equity bonuses and default-related provisions.
- Assess cash runway, financing requirements, and whether the company raised enough capital to meet near-term obligations after the filing date.
- Verify hospital evaluation outcomes, billable orders, production capacity, unit economics, and recurring cleaning-kit sales; the filing provides no clear quantified forward sales guidance.
- Review remediation of the material weakness and the effect of stock-based compensation and equity-linked instrument valuations on reported results.
- Check the status and potential financial impact of the former employee lawsuit and any patent-related disputes or royalties.